Related Experiment Video
Updated: May 19, 2026
10:34
Measurement of Differentially Methylated INS DNA Species in Human Serum Samples as a Biomarker of Islet β Cell Death
Published on: December 21, 2016
Gene expression changes in human islets exposed to type 1 diabetic serum.
Andrew M Jackson1, Mazhar A Kanak, Ellen K Grishman
1Institute of Biomedical Studies, Baylor University, Waco, TX, USA.
Islets
|August 14, 2012
Summary
Type 1 diabetes mellitus serum triggers complement deposition and alters islet cell gene expression, leading to significant graft loss. This study identifies key genes involved in this destructive process, offering targets for improved islet transplantation outcomes.
Area of Science:
- Immunology
- Endocrinology
- Molecular Biology
Background:
- Islet cell transplantation faces challenges due to early graft loss.
- Complement cascade and coagulation factors are implicated in islet graft destruction.
Purpose of the Study:
- To analyze gene expression changes in human islet cells exposed to type 1 diabetes mellitus serum.
- To identify molecular mechanisms underlying T1DM serum-induced islet cell damage.
Main Methods:
- Human pancreatic islet cells cultured and treated with autologous, allogeneic, or T1DM patient serum.
- Complement deposition assessed via immunofluorescence and CH50 assay.
- Gene expression analyzed using Illumina micro-array and confirmed with real-time PCR.
Main Results:
- T1DM serum induced complement deposition on islet cells.
- Microarray and PCR identified 50 predictive genes, with significant upregulation of MMP9, IL-1β, IL-11, IL-12A, and RAD.
- Downregulation of IL-1RN observed in T1DM serum-treated islets.
- Overexpression of angiogenesis-related genes and decreased expression of protective genes noted.
Conclusions:
- T1DM serum significantly impacts islet cell gene expression, promoting inflammation and angiogenesis while reducing protective mechanisms.
- These findings highlight potential therapeutic targets to mitigate islet graft loss in type 1 diabetes mellitus.
Related Concept Videos
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.